Incretin Atlas › Trials › SURMOUNT-OSA
SURMOUNT-OSA
Tirzepatide · Obstructive sleep apnoea + obesity
Design
- Molecule(s)
- Tirzepatide
- Population
- Obstructive sleep apnoea + obesity
- Official title
- Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed · 2022-06 → 2024-03
- Participants
- 469
- Duration
- 52 weeks
- Registry
- NCT05412004
Outcomes in the indication
SURMOUNT-OSA Tirzepatide · Obstructive sleep apnoea + obesity · 52 weeks · n = 469 seed
AHI −25.3 vs −5.3 events/h (trial 1), −29.3 vs −5.5 (trial 2, on PAP); FDA label Dec 2024
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Apnea-hypopnea index, change from baseline trial 1 week 52 | −25.3 | −5.3 | −20.0 (−25.8 to −14.2) events/h | verified |
| Apnea-hypopnea index, change from baseline trial 2 week 52 | −29.3 | −5.5 | −23.8 (−29.6 to −17.9) events/h | verified |
Verbatim quotes (2)
- Apnea-hypopnea index, change from baseline
In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2)
- Apnea-hypopnea index, change from baseline
In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: SURMOUNT-OSA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-osa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.